




A




B



C



D



Supplemental Figure Legend. A) Analysis of GIP production to complement the main figure, panel F, illustrating that participants taking TNFi but not other treatment regimens broken out here showed a distinct pattern of GIP production. GLP-2 (panel B) and GLP-1 (panel C) levels in plasma were also quantified in plasma during the postprandial time course and plotted to show distinct treatment groups. D) Plasma apoB48 levels in the time course did not differ between any groups, including CD participants taking TNFi (green symbols), all other CD participants (black symbols), or control participants (open symbols). Friedman tests were performed for all panels. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$. The absence of a symbol for statistical significance indicates that statistically significant differences were not found.